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Timing of Antiretroviral Therapy and 
Systemic Inflammation in Sub-Saharan 
Africa: Results From the META 
Longitudinal Cohort Study
Mark J. Siedner,1,2,3,4 Mwebesa Bosco Bwana,3 Stephen Asiimwe,3,5  
Gideon Amanyire,3 Nicholas Musinguzi,3 Jose Castillo-Mancilla,6 Russell P. Tracy,7 
Ingrid T. Katz,1,8 David R. Bangsberg,9 Peter W. Hunt,10 Catherine Orrell,11 and 
Jessica E. Haberer1,2; on behalf of the META study investigatorsa
1Harvard Medical School, 2Massachusetts General Hospital, and 8Brigham and Women’s 
Hospital, Boston,  6University of Colorado, Denver, 7University of Vermont, Burlington, 9Oregon 
Health & Science University-Portland State University School of Public Health, Portland, and 
10University of California, San Francisco; 3Mbarara University of Science and Technology and 
5Kabwohe Clinical Research Center, Uganda; 4Africa Health Research Institute, Kwa-Zulu 
Natal, and 11University of Cape Town, South Africa
Chronic inflammation predicts complications in persons with 
human immunodeficiency virus infection. We compared 
D-dimer, soluble CD14, and interleukin 6 levels before and 
12 months after antiretroviral therapy (ART) initiation, among 
individuals starting ART during earlier-stage (CD4 T-cell 
count >350/µL) or late-stage disease (CD4 T-cell count <200/
µL). Female sex, older age, viral load, and late-stage disease 
were associated with pre-ART biomarkers (n = 661; P <  .05). 
However, there were no differences in biomarkers by disease 
stage after 12 months of ART (n = 438; P > .05), owing to loss 
from observation and greater declines in biomarkers in late-
stage initiators (P < .001). Earlier initiation of ART is associated 
with decreased inflammation, but levels seem to converge be-
tween earlier and later initiators surviving to 12 months.
Keywords.  HIV; inflammation; immune activation; anti-
retroviral therapy; Uganda; South Africa.
Early initiation of antiretroviral therapy (ART) in sub-Saharan 
Africa results in improved immune reconstitution, reductions 
in biomarkers of inflammation, and reductions in AIDS events 
[1]. However, it is less certain how the timing of ART initiation 
affects the degree of chronic inflammation among persons living 
with human immunodeficiency virus (HIV) in the region [2]. 
Even less is known about how the timing of ART affects chronic 
HIV complications in sub-Saharan Africa, where individuals 
continue to present to care with relatively advanced disease [3].
We leveraged a multinational cohort study in sub-Saharan 
Africa with longitudinal observation of individuals initiating 
ART at earlier-stage versus late-stage disease to understand how 
ART timing affects biomarkers of immune activation before and 
12 months after ART initiation. We hypothesized that individuals 
starting ART during late-stage disease would have higher levels 
of biomarkers before treatment and that this difference would not 
be resolved after 12 months of suppressive therapy.
METHODS
Study Setting and Participants
The Monitoring of Early Treatment Adherence (META) study 
was an observational longitudinal cohort study designed to 
discern how timing of ART initiation and pregnancy affect 
ART adherence in Uganda and South Africa. Full protocol 
details have been published elsewhere [4]. For this analysis, 
we included individuals in the late-stage disease (nonpregnant 
with a CD4 T-cell count  <200/µL) and earlier-stage disease 
(nonpregnant with a CD4 T-cell count  >350/µL and World 
Health Organization stage I) subgroups. Participants were 
observed at the start of treatment and again at 6 and 12 months 
for completion of surveys and blood collection.
Laboratory Methods
CD4 T-cell counts were measured using the PIMA assay (Alere 
Diagnostics). HIV-1 RNA viral load (VL) was measured with the 
Cobas Taqman platform in Uganda and the Roche CAP/CTM 
HIV-1 v2 platform in South Africa. We defined viral suppression 
as <39 copies/mL in South Africa and <33 copies/mL in Uganda. 
We excluded participants with viral suppression at enrollment. 
Blood at each visit was collected into ethylenediaminetetraacetic 
acid tubes, immediately centrifuged for plasma separation, and 
stored at −80oC. We tested cryopreserved plasma for 3 biomarkers: 
(1) interleukin 6 (IL-6) (MesoScale Discovery); (2) soluble CD14 
(sCD14; R&D Systems); and (3) D-dimer (Diagnostica Stago). 
We imputed the minimum and maximum limits of quantifica-
tion for each assay for results out of range (500 and 3500  ng/
mL for sCD14, 0.01 and 20 μg/µL for D-dimer). No participants 
had out-of-range IL-6 levels. Biomarkers were selected for their 
association with HIV infection, and because each has been pre-
dictive of long-term chronic comorbid conditions and/or death 
[5–7]. Biomarkers were tested at the University of Vermont 
Laboratory for Clinical Biochemistry Research.
Statistical Methods
We fit 3 sets of linear regression models with the following 
outcomes of interest: (1) each biomarker before ART initiation; 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
BRIEF REPORT • jid 2019:220 (1 October) • 1173
(2) each biomarker after 12  months of ART, restricted to 
those with 12-month viral; and (3) changes in each biomarker 
from before treatment to 12  months, restricted to those with 
12-month viral suppression. Biomarkers were log-transformed 
and divided by their interquartile range (IQR), such that each 
1-unit increase in the coefficient represents an increase in log-
transformed biomarker IQR [8, 9].
Our primary explanatory variable was earlier- versus late-
stage disease subgroup. Models were fit with and without poten-
tial confounders, including age (10-year increments), country, 
sex, current smoking, body mass index, and pretreatment VL 
(log10). We graphically depicted adjusted changes in biomarkers 
over time and by subgroup using postregression margins. To 
assess the potential bias due to loss from observation and death 
before 12 months, we compared pretreatment biomarkers be-
tween those with and without inflammatory data at 12 months. 
In secondary analyses, we repeated the models of change in 
biomarkers with a sex-by-subgroup, age-by-subgroup (using 
the median cohort age of 33 years), or a country-by-subgroup 
interaction term. Finally, we repeated models after removing 
pretreatment VL as a confounder and without restricting the 
cohort to those who achieved 12-month viral suppression.
Ethical Considerations
Study procedures were approved by Partners Healthcare, 
the Mbarara University of Science and Technology, Uganda 
National Council for Science and Technology, University of 
Cape Town, and Western Cape province in South Africa. All 
participants provided written informed consent.
RESULTS
We enrolled 699 individuals in the earlier-stage (n  =  335) or 
late-stage (n = 364) disease groups (Supplementary Figure 1). 
Of these, 661 (95%) had pretreatment biomarker testing, had 
a detectable VL at enrollment, and were included in our pre-
treatment analyses. Our primary 12-month analytic data set 
included 438 individuals (79%) who completed 12-month bio-
marker testing and achieved virologic suppression at 12 months. 
Of these, 113 were excluded from the 12-month primary anal-
ysis for a detectable VL at study conclusion. Another 110 were 
excluded from 12-month analyses, with the most common 
reasons being death (n = 34) and lack of plasma for biomarker 
testing (n = 43).
The median age of the cohort was 33  years, approximately 
60% were female. and the study was approximately evenly di-
vided between participants from Uganda and South Africa 
(Supplementary Table 1A and 1B). The median CD4 T-cell 
counts in the earlier- and late-stage subgroups were 427/µL and 
118/µL, respectively. All participants were started on a regimen 
of efavirenz, tenofovir, and emtricitabine. Individuals in the 
earlier-stage group were more likely to be female and had lower 
pretreatment VL (P < .001).
Individuals starting ART during earlier-stage disease had 
lower levels of all 3 biomarkers before ART treatment than the 
late-stage group (P <  .001; Table 1 and Supplementary Figure 
2). These relationships were persistent after adjustment for 
confounders, such that initiating ART with late-stage disease 
was associated with a mean increase of 0.5–1.5 times the IQR for 
each biomarker. In all models, pretreatment VL was associated 
with increased levels of biomarkers. In adjusted models, older 
individuals had higher pretreatment levels of D-dimer and IL-6, 
women had higher levels of D-dimer, and participants in South 
Africa had lower levels of sCD14 than those in Uganda.
When comparing pretreatment biomarkers between patients 
who were retained in care and underwent testing at 12 months 
(n = 438) and those lost to observation or with detectable VL 
at 12 months (n = 223), we found higher levels of pretreatment 
biomarkers among those who were lost to observation in the 
late-stage group (all P < .01; Supplementary Figure 3). This as-
sociation was not observed among those in the earlier-stage 
group. Among participants who survived and achieved viral 
suppression at 12  months, we found no differences in levels 
of any biomarker between those in the earlier-and late-stage 
groups (P > .05; Table 2 and Figure 1). 
The equivalence between subgroups at 12  months was 
explained by greater decreases in each of the biomarkers from 
before treatment to 12 months among individuals in the late-
stage subgroup (P <  .003 for all biomarkers; Table 3). Female 
sex (D-dimer), active smoking (sCD14), and a higher pretreat-
ment VL (sCD14, IL-6, and D-dimer) were associated with 
higher biomarker levels at 12  months. The relationship with 
country of origin was inconsistent, with South Africans having 
lower levels of sCD14, but higher levels of IL-6. We found no 
meaningful differences in these relationships in sensitivity 
analyses, including those with a detectable VL at 12  months 
(Supplementary Table 2) and without inclusion of pretreatment 
VL (Supplementary Table 3). We found similar relationships be-
tween disease stage at ART initiation and changes in biomarkers 
from before treatment to 12 months in analyses stratified by sex, 
country of origin, and age (Supplementary Figure 4).
DISCUSSION
This study showed that individuals in Uganda and South 
Africa starting ART with late-stage disease have significantly 
higher levels of sCD14, IL-6, and D-dimer than those starting 
ART during earlier stages of disease, and it offers additional 
evidence of the many benefits of earlier ART initiation in the 
region. However, contrary to our hypothesis, among those 
who survive and achieve viral suppression at 12 months, we 
found no difference in levels of biomarkers comparing those 
initiating treatment with earlier- or late-stage disease 1  year 
after treatment initiation. This result seemed to be driven by 
2 phenomena: (1) loss from care and death in those with the 
greatest inflammation in the late-stage group and (2) greater 
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decreases in biomarkers in the late-stage disease group among 
those who survived and remained in care at 12 months. Our 
findings offer promise that, among survivors after late-stage 
disease initiation, effective ART might reduce long-term 
consequences of chronic inflammation in those who achieve 
viral suppression.
Similar to our study, individuals in both the Men’s AIDS 
Cohort Study (MACS) and the Women’s Interagency Health 
Study (WIHS) had significant reductions in most inflamma-
tory biomarkers after ART initiation [10]. However, unlike 
those studies, we detected a decrease in IL-6 after ART initia-
tion, which might be due to our use of analyte-specific enzyme-
linked immunosorbent assay platforms, which are typically 
more sensitive to changes in biomarkers than multiplex assays. 
Alternatively, these differences might be because the MACS and 
WIHS cohorts observed individuals with relatively high CD4 
T-cell counts at ART initiation compared with ours (median 
cohort CD4 T-cell count, approximately 300–500/µL and 187/
µL, respectively). Notably, the lack of a decrease in sCD14 seen 
among earlier-stage initiators in our cohort has been reported 
elsewhere and might be due to muted reductions with efavirenz-
based ART [11]. This finding argues for additional investiga-
tion, given broad use of efavirenz globally and its associations 
with poor outcomes [6].
Unlike studies from other settings, in this cohort from 
Africa, we found accentuated reductions in biomarkers in 
late-stage disease initiators, such that there were no difference 
in biomarkers in those surviving and achieving viral suppres-
sion after 12  months. In contrast, large reductions in T-cell 
activation, sCD14, soluble CD163, and D-dimer have been 
documented with earlier treatment initiation in other settings 
[12]. As with the WIHS and MACS cohorts, a notable contrast 
between these studies and ours was the relatively high CD4 
T-cell counts in those studies.
An unexpected finding in our study was the difference seen 
in biomarkers both before and after ART between Uganda and 
South Africa, which varied by biomarker (eg, higher sCD14 and 
lower IL-6 levels in Uganda versus South Africa). Although we 
cannot readily explain these findings, they reinforce the need 
to consider region-specific relationships between HIV, ART, 
and these biomarkers. If on-treatment inflammation does pre-
dict future events in this region, our data support a potentially 
similar benefit of ART in both earlier- and late-stage disease 
treatment initiators who survive and attain virologic suppres-
sion. There are suggestions from Western settings that levels 
of inflammation after ART initiation are potentially more pre-
dictive of future complications than pretreatment levels [13]. 
Similarly, our group previously reported that changes in sCD14 
and the ratio of kynurenine to tryptophan (KT ratio) 6 months 
after treatment, but not before treatment, were predictive of 
increased carotid intima media thickness years later in Uganda 
[9] and that higher levels of KT ratio, sCD14, IL-6 and D-dimer 
were associated with a greater risk of mortality 6 months after 
ART initiation [14].
Our results should also be considered generalizable to 
individuals in similar settings who complete 12 months of therapy 
and achieve virologic suppression. Notably, loss from observa-
tion occurred in approximately 20% of individuals in our ana-
lytic cohort, including excess deaths in the late ART group, which 
may have inflated the extent of observed declines in biomarkers. 
Although residual or unmeasured confounding might explain 
associations between treatment stage and biomarkers, our ef-
fect sizes for both pretreatment and on-treatment estimates were 
large enough (most P < .003) that a confounder of a large effect 
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size would be needed to significantly alter our conclusions. We 
selected plasma soluble markers known to be associated with 
non-AIDS events, but other biomarkers that reflect distinct bi-
ologic pathways but also predict disease (eg, soluble tumor ne-
crosis factor receptor and KT ratio), may behave differently. 
Furthermore, immune activation in lymphoid and other tissues 
that theoretically contribute to disease are not fully reflected by 
plasma biomarkers [15].
In summary, we report data from a multicenter longitudinal 
cohort in Africa, demonstrating that late initiation of ART is 
associated with increased systemic inflammation. However, 
in those who remain alive and achieve virologic suppression 
at 12 months, biomarker levels between earlier- and late-stage 
initiators converge at 12 months. The long-term consequences 
of these findings, and particularly if inflammatory biomarkers 
after suppressive ART continue to predict clinical outcomes in 
the region, is a critical area for future study.
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